News articles about Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biohaven Pharmaceutical Holding Co earned a media sentiment score of 0.33 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0592044809408 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Biohaven Pharmaceutical Holding Co (BHVN) traded up 0.24% on Friday, reaching $36.88. 40,270 shares of the company’s stock traded hands. The company’s 50-day moving average is $31.72 and its 200-day moving average is $26.70. Biohaven Pharmaceutical Holding Co has a 52 week low of $17.00 and a 52 week high of $38.86. The firm’s market capitalization is $1.33 billion.

BHVN has been the subject of several recent analyst reports. Needham & Company LLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set a “buy” rating and a $30.00 price objective for the company. BidaskClub lowered shares of Biohaven Pharmaceutical Holding Co from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Piper Jaffray Companies reissued a “buy” rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, September 12th. Zacks Investment Research raised shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Finally, William Blair initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “outperform” rating and a $46.00 price objective for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $43.25.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/09/23/positive-press-coverage-somewhat-unlikely-to-affect-biohaven-pharmaceutical-holding-co-bhvn-share-price.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.